Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma.
Peter
P
Moosmann
Marc
M
Heizmann
Nina
N
Kotrubczik
Martin
M
Wernli
Mario
M
Bargetzi
D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D015331:Cohort Studies; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage*; D011480:Protease Inhibitors / Q000008:administration & dosage; D011719:Pyrazines / Q000008:administration & dosage*; D012008:Recurrence; D016896:Treatment Outcome
D001897:Boronic Acids; D009588:Nitrogen Mustard Compounds; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D000069461:Bendamustine Hydrochloride